Erin Hofstatter - Concepedia

Author

Erin Hofstatter

Also Known As

E Hofstatter, E. W. Hofstatter, Erin Hofstatter, Erin W Hofstatter, Erin W. Hofstatter, Erin Wysong Hofstatter, Hofstatter, Erin

109

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Yale Cancer Center Yale University Beth Israel Deaconess Medical Center The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute

About

Erin Hofstatter is an author at Yale Cancer Center specializing in breast cancer, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	14	1.6K
2	Public Health	3	3	37
3	Health Sciences	2	2	35
4	Arts	1	1	33
5	Cell Biology	1	1	21

Erin Hofstatter

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Impact of Financial Burden of Cancer on Survivors' Quality of Life Kathleen Fenn, Suzanne B. Evans, Ruth McCorkle, Journal of Oncology Practice	2014	459
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline Nadine Tung, Judy C. Boughey, Lori J. Pierce, Journal of Clinical Oncology	2020	307
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update Kala Visvanathan, Carol J. Fabian, Elissa Bantug, Journal of Clinical Oncology	2019	192
PALB2 mutations in familial breast and pancreatic cancer Erin Hofstatter, Susan M. Domchek, Alexander Miron, Familial Cancer Tumor BiologyPancreatic CancerCancer PathologyPathologyBreast Cancer	2011	155
Understanding Patients' Attitudes Toward Communication About the Cost of Cancer Care Andrea J. Bullock, Erin Hofstatter, Melinda Yushak, Journal of Oncology Practice	2012	146
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial) Nadine Tung, Banu Arun, Michele R. Hacker, Journal of Clinical Oncology	2020	125
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice Laura N. Burga, Hai Hu, Ashish Juvekar, Breast Cancer Research	2011	84
Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability Prudence Lam, Laura N. Burga, Bryan P Wu, Molecular Cancer	2008	74
Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer Christos Hatzis, W. Fraser Symmans, Ya Zhang, Clinical Cancer Research	2015	63

Page 1